Please assess the completion status of the following clinical trial:

Trial Title: Beta-blockers in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* WHO category 1 pulmonary arterial hypertension (Nice 2013)~* WHO functional class II-III~* RVEF by cardiac MRI \< 45%~* Stable on PAH-specific therapy as defined by no change in PAH-specific treatment and functional class in the past 3 months. Patient can be on either mono or combination PAH-specific therapy~Exclusion Criteria:~* Subjects will be excluded from participation in the study if any of the following conditions exist:~* Significant persistent bradycardia (resting heart rate \< 60 bpm) without a permanent pacemaker~* Second or third degree AV block without a permanent pacemaker~* Significant sinus tachycardia (resting heart rate \> 110 bpm)~* Use of anti-arrhythmic drugs~* Hypotension defined as systolic blood pressure \< 100 mmHg at the time of enrollment~* Significant illness in the past 30 days requiring hospitalization~* Acute decompensated right heart failure within past 30 days~* Known allergy or intolerance to carvedilol or other β blockers~* Cardiac index \< 2 l/min/m2 or right atrial pressure \> 15 mm Hg by right heart catheterization within last 3 months~* Asthma~* Positive pregnancy test in patients of child bearing-potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carvedilol First (Type: EXPERIMENTAL): Crossover Design: Participants receive Carvedilol first and placebo second
- Placebo First (Type: PLACEBO_COMPARATOR): Crossover Design: Participants receive placebo first and Carvedilol second

Based on this trial design, predict the completion outcome and termination type (if applicable).